Roche Elecsys | Roche Elecsys | Abbott | Abbott | |
| Platform | Roche e801 | Roche e801 | Abbott Architect | Abbott Architect |
| Assay type | Electrochemiluminescence immunoassay (ECLIA) | Electrochemiluminescence immunoassay (ECLIA) | Chemiluminescent Microparticle Immunoassay (CMIA) | Chemiluminescent Microparticle Immunoassay (CMIA) |
| Reporting format | QUANTITATIVE | Qualitative | Qualitative | Qualitative |
| Reporting ranges | Positive with value reported in U/ml / Negative | Positive / Negative | Positive / Negative | Positive / Negative |
| Antigen used | Spike protein receptor binding domain (RBD) | Nucleocapsid | Nucleocapsid | Spike protein |
| Analyte target | SARS-CoV-2 Antibodies (IgG/IgM) Total antibodies | SARS-CoV-2 Antibodies (IgG/IgM) Total antibodies | SARS-CoV-2 Antibodies (IgG) | SARS-CoV-2 Antibodies (IgM) |
| Sample type verified | Serum – venous | Serum – venous | Serum – venous | Serum – venous |
| Sensitivity | 99.8% | 97.4% | 97.5% | 96.67% in samples taken more than 14 days post symptoms onset |
| Specificity | 98.8% in samples taken 14 days or later after positive PCR | 100% | 99.1% | 99.0% |
| Seasonal Corona Virus panel | 24/24 Negative | 26/26 Negative | 26/26 Negative | N/A |
